EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

CORESTEM Inc (166480) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of CORESTEM Inc KRW 649, price KRW 2,315, upside -72.0%, quality 14 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7166480004

CI Thin data Oct 2, 2026

CORESTEM Inc

166480 · KQ

Weakest SetupStrongly overvalued and low quality.

Low debt
Fair value 648.89 KRW · Strongly overvalued (−72.0%)
Quality 14/100
Weak Growth (revenue 5y −5.2 %/yr in KRW)
Loss-making · -152.0% net margin (TTM)
Negative free cash flow
Trails peers (0/8)
Narrow moat 9/100
Thin data
⚠ Dilution
Watch CORESTEM Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

19,338 KRW 1,060 KRW Fair Value 648.89 KRW May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.

How to read this chart

60‑month range 1,060 KRW – 19,338 KRW · fair‑value band 484.25 KRW – 968.50 KRW · the 2,315 KRW price screens above the 648.89 KRW fair value. Dashed = 300-day average. As of Oct 2, 2026.

Follow CORESTEM in your weekly email

Every Wednesday you see whether CORESTEM is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS).

Show more

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases. The company has a strategic partnership with ATG Lifetech to deliver precision-driven non-clinical solutions to pharmaceutical companies and biotech ventures. The company was formerly known as Corestem, Inc. CORESTEMCHEMON Inc. was founded in 2003 and is based in Seongnam-si, South Korea.

Stock analysis

CORESTEM Inc (166480) currently trades at 2,315 KRW, while our model-based Fair Value estimate is 648.89 KRW, 72.0% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 484.25 KRW (bear) to 968.50 KRW (bull), the price of 2,315 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 14/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

CORESTEM Inc reported revenue of 20.2B KRW in FY2025 versus 30.2B KRW in FY2021, a compound −9.6%/yr. Reported net income was −26.8B KRW in FY2025.

Key figures

Market cap 110B KRW (≈ $81.7M) · P/S ratio 6.01 · Net margin −133% · Return on equity −62.0% · Return on assets (EBIT) −16.2% · Operating margin −79.3% · Revenue (TTM) 18.3B KRW · Revenue growth (YoY) −1.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 52% below its 52-week high and 118% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −72%, 166480 screens richer than that median.

Fair Value models

Bear 484.25 KRW Fair Value 648.89 KRW Bull 968.50 KRW
Price 2,315 KRW · Upside -72.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 573.58 KRW 768.60 KRW 1,147 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 573.58 KRW 768.60 KRW 1,147 KRW 54

Open the full fair value analysis →

Notify me when 166480 reaches fair value

Put 166480 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 14/100

Of which business quality 14 · Market factors (momentum, volatility) 37

Profitability 1
Margins and returns on capital today
Quality Growth 10
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 36
Balance sheet, leverage, solvency risk
Investment 47
Disciplined investing over empire-building
Low Volatility 8
Calm price path (market factor)
Momentum 50
Price trend over the last 3–12 months (market factor)
52W Momentum 48
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−29.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−24.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.2%
Start year 2020 (pandemic). Over 10 years: +0.8% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−26.6% (2020) → −105.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

166480 screens overvalued: fair value 72% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare CORESTEM Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 609 stocks

Beats the industry median on 0/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 14 · Bottom 25%
Fair Value upside −72.0% · Below median
Profitability
Return on assets −12.0% · Below median
Net margin (TTM) −152.0% · Bottom 25%
Operating margin (TTM) −79.3% · Bottom 25%
Growth and dividend
Revenue growth −1.7% · Below median
Balance sheet
Debt / equity 0.21× · Above median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)89 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $504.73 $555.20 +10%
Regeneron Pharmaceuticals, Inc REGN $735.20 $1,275 +73%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CORESTEM Inc · Fair Value
648.89 KRW −72%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "CORESTEM Inc Fair Value". https://www.fairvalue-calculator.com/stock/166480

Frequently asked questions

Is CORESTEM Inc (166480) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of 648.89 KRW versus a price of 2,315 KRW, about −72% upside (overvalued).
What is the fair value of 166480?
Our model-based fair value for CORESTEM Inc is 648.89 KRW (as of Oct 2, 2026), built from audited fundamentals. The current price: 2,315 KRW.
What is the quality score of 166480?
CORESTEM Inc has a Quality Score of 14/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CORESTEM Inc (166480)?
Our model-based price target is the fair value of 648.89 KRW (as of Oct 2, 2026) from 1 valuation models. Cautious scenario 484.25 KRW, optimistic scenario 968.50 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the CORESTEM Inc stock forecast for 2026?
Our models put fair value at 648.89 KRW, about −72% upside versus a price of 2,315 KRW (overvalued). Cautious scenario 484.25 KRW, optimistic scenario 968.50 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of CORESTEM Inc (166480)?
CORESTEM Inc reported trailing-twelve-month revenue of about 18.3B KRW (latest available figure, as of Oct 2, 2026).
What is the intrinsic value of CORESTEM Inc (166480)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CORESTEM Inc it is 648.89 KRW per share (as of Oct 2, 2026), against a price of 2,315 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is CORESTEM Inc stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 166480 trades above its calculated fair value: price 2,315 KRW, fair value 648.89 KRW, a gap of about −72% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 166480?
No. The price is what the market pays today (2,315 KRW); the fair value is what the company's own numbers justify (648.89 KRW). For CORESTEM Inc the two are 1,666 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is CORESTEM Inc worth?
The market values CORESTEM Inc at about 110B KRW (market capitalisation, as of Oct 2, 2026). Per share that is 2,315 KRW; our models calculate a fair value of 648.89 KRW per share.
What do the bullish and bearish scenarios say about 166480?
Our models span a range for CORESTEM Inc: cautious scenario 484.25 KRW, base 648.89 KRW, optimistic 968.50 KRW per share (as of Oct 2, 2026, price 2,315 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CORESTEM Inc (166480)?
Balance-sheet figures for CORESTEM Inc (as of Oct 2, 2026): return on equity −62.0%, debt of 0.21 per unit of equity. They feed the Quality Score of 14/100, which measures business quality independently of the share price.
How far is 166480 from its 52-week high?
CORESTEM Inc trades at 2,315 KRW, about 52% below its 52-week high of 4,800 KRW and 118% above the low of 1,060 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 648.89 KRW is for.
Which stocks are comparable to CORESTEM Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CORESTEM Inc stock attractive at the current price?
The data as of Oct 2, 2026: price 2,315 KRW, calculated fair value 648.89 KRW (−72%), Quality Score 14/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 166480 calculated?
We run CORESTEM Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 648.89 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1 % above its aggregate fair value. CORESTEM Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CORESTEM Inc (166480)?
The closing price on Oct 2, 2026 was 2,315 KRW. Our model-based fair value is 648.89 KRW, about −72% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CORESTEM Inc right now?
The price sits above even our optimistic bull case (968.50 KRW). The favourable scenario is already priced in. Weak quality (14/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (484.25 KRW to 968.50 KRW) leaves room in how you read the outcome.

Key figures of CORESTEM Inc

How large is the market capitalisation of CORESTEM Inc (166480)?
The market capitalisation of CORESTEM Inc is 110B KRW (≈ $81.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CORESTEM Inc (166480)?
The price-to-sales ratio of CORESTEM Inc is 6.01 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of CORESTEM Inc (166480)?
The net margin of CORESTEM Inc is −133% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of CORESTEM Inc (166480)?
The return on equity (ROE) of CORESTEM Inc is −62.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CORESTEM Inc (166480)?
On an EBIT basis the return on assets of CORESTEM Inc is −16.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CORESTEM Inc (166480)?
The operating margin of CORESTEM Inc is −79.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CORESTEM Inc (166480)?
Revenue at CORESTEM Inc is growing −1.7% versus a year earlier (3y avg −24.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does CORESTEM Inc (166480) generate?
The free cash flow of CORESTEM Inc is −15.9B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does CORESTEM Inc (166480) carry?
The net debt of CORESTEM Inc is 35.9B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch CORESTEM Inc in the live analysis

One click puts CORESTEM Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.